The rise of Sildenafil initially sparked a surge for the drug industry, but recent changes present a uncertain outlook for those considering a stake. Generic alternatives are eroding profits, and continued litigation https://larapumw093789.uzblog.net/the-blue-pill-and-pharma-a-risky-investment-54819550